Co-inhibitory profile and cytotoxicity of CD57+PD-1– T cells in end-stage renal disease patients
Clinical and Experimental Immunology , Volume 191 - Issue 3 p. 363- 372
Blockade of the CD80/86-CD28 pathway by belatacept after kidney transplantation is associated with an increased risk of rejection compared with standard, calcineurin inhibitor (CNI)-based therapy. CD28– T cells, which express CD57, are not susceptible to belatacept treatment. High numbers of CD4+CD57+programmed death 1 (PD-1)– T cells pretransplantation have been associated with a higher chance of rejection, although conflicting data have been reported. To investigate the working mechanism behind this possible higher chance of rejection, we studied the expression of co-inhibitory molecules (CD223, CD244 and PD-1), proliferative capacity and cytotoxic potential of fluorescence activated cell sorted (FACS) CD4+CD57+PD-1– and CD8+CD57+PD-1– T cells, and their CD57– control populations, after alloantigen stimulation. The effect of belatacept on the cytotoxic capacity of pretransplantation peripheral blood mononuclear cells from 20 patients who received belatacept post-transplantation was also tested. Expression of co-inhibitory molecule CD223 increased by approximately 10-fold after allogeneic stimulation in all four T cell subsets. Proliferation and up-regulation of CD244 and PD-1 was observed for CD4+CD57-PD-1– T cells after allogeneic stimulation, but no up-regulation of these markers occurred on CD8+ T cells or CD4+CD57+PD-1– T cells. However, CD4+CD57+PD-1– T cells and, to a lesser extent, CD8+CD57+PD-1– T cells displayed higher cytotoxicity as indicated by granzyme B expression. Belatacept inhibited the cytotoxic potential of CD4+CD57+PD-1– T cells (median of inhibition 31%, P < 0·01) and CD8+CD57+PD-1– T cells (median of inhibition 10%, P < 0·05). In conclusion, alloantigen-activated CD4+CD57+PD-1– T cells exhibited a less proliferative but more cytotoxic profile than their CD57– counterparts. Their cytotoxic capacity can be inhibited partly by belatacept and was not associated with development of rejection after kidney transplantation.
|, , ,|
|Clinical and Experimental Immunology|
|Organisation||Department of Internal Medicine|
Kraaijeveld, R, de Graav, G.N, Dieterich, M, Litjens, N.H.R, Hesselink, D.A, & Baan, C.C. (2018). Co-inhibitory profile and cytotoxicity of CD57+PD-1– T cells in end-stage renal disease patients. Clinical and Experimental Immunology, 191(3), 363–372. doi:10.1111/cei.13070